Results 251 to 260 of about 25,462,782 (297)

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Inertia and Rapid Divergence in the Evolution of Yawning: A Comparison Between Two Closely Related but Socially Different Monkeys. [PDF]

Am J Primatol
Pedruzzi L, Maglieri V, Oliveri P, Francesconi M, Riccobono R, Bigozzi F, Lemasson A, Palagi E.   +7 more
europepmc   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

A recent update on the morphological classification of intraductal papillary neoplasm of the bile duct: Correlation with postoperative prognosis and pathological features. [PDF]

PLoS One
Noguchi D, Kuriyama N, Kozuka Y, Komatubara H, Sakamoto T, Ito T, Hayasaki A, Iizawa Y, Fujii T, Tanemura A, Murata Y, Kishiwada M, Mizuno S.   +12 more
europepmc   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Computational investigation unveils pathogenic LIG3 non-synonymous mutations and therapeutic targets in acute myeloid leukemia. [PDF]

PLoS One
Hossen MA, Jahan UMS, Hossain MA, Asif KH, Rahman A, Ahmed S, Uddin MM, Amin MF, Barik MA, Islam MJ, Kamruzzaman M, Hasnat S, Uddin MN, Islam T, Hoque MN.   +14 more
europepmc   +1 more source

Effects of Season, Age, and Stage of Lactation upon Type Ratings of Holstein Cows

, 1958
C.J. Wilcox, K.O. Pfau, R.E. Mather, John Bartlett   +3 more
openalex   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Brain [¹⁸F]FDG uptake patterns in type 2 diabetes: new phenotypes relating to biomarkers of cognitive impairment. [PDF]

Brain Commun
Martín-Saladich Q, Pareto D, Simó R, Ciudin A, Aparicio C, Hammawa K, de la Calle Vargas E, Aguadé-Bruix S, Giralt M, Ramirez-Serra C, González Ballester MA, Herance JR.   +11 more
europepmc   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source